A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients by Xinna Zhou et al.
Zhou et al. SpringerPlus  (2015) 4:803 
DOI 10.1186/s40064-015-1603-5
RESEARCH
A phase I dose-escalation study of a 
biosimilar trastuzumab in Chinese metastasis 
breast cancer patients
Xinna Zhou1,2†, Jing Yu1†, Wenmiao Wang3, Guohong Song1, Xiaoli Wang1,2, Jun Ren1,2*, Lijun Di1* 
and Xinghe Wang3*
Abstract 
Trastuzumab has been widely used among the breast cancer patients with human epidermal growth factor receptor 
2 (HER2) overexpression. The genetically engineered trastuzumab traded as Cipterbin® was developed in China since 
2003. We have disclosed the phase I clinical trial data of safety, pharmacokinetic profile (PK) in patients with metastasis 
breast cancer. Subjects identified as HER2 strong positive received single intravenously doses of 100, 250 or 500 mg 
Cipterbin® in dose-escalation manner. The safety evaluations were recorded and plasma concentration profiles for 
the drug were analyzed. 27 Chinese metastatic breast cancer patients were enrolled in this study. Patients in each 
group of different dosage were well-tolerated. The most frequently drug-related adverse events were fever (59.3 %), 
transaminase increased (22.2 %), chills (18.5 %) and arrhythmia (18.5 %). Only one patient with severe adverse event 
was observed in 250 mg group revealing brachycardia. PK profile analysis showed that sera steady concentration 
could be reached in dose-proportional manner, except volume of distribution (Vd) and clearance (CL), which reached 
peak values at 250 mg administration cohort. This genetically engineered HER2-target antibody had demonstrated 
the accepted safety with well-tolerated.
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Background
Trastuzumab is an IgG1 humanized monoclonal 
antibody that binds the extracellular domain of the 
human epidermal growth factor receptor 2 (HER2), 
disrupting the normal regulatory functions of HER2 
signal pathways(Yarden and Sliwkowski 2001). Approxi-
mately 20–25  % breast patients are identified as HER2 
overexpressed, which associated with high recurrence 
and shorten overall survival (OS) (Li and Li 2013; Kong 
et al. 2013).
Previous studies demonstrate that the addition of tras-
tuzumab (Herceptin, F. Hoffmann-La Roche, Basel, Swit-
zerland) to chemotherapy could significantly prolong the 
time of disease progression, duration of response and 
OS of metastatic breast cancer patients (Boekhout et al. 
2011). Nowadays, the treatments of trastuzumab-con-
taining regimens have been recognized as the standard of 
care in the treatment of HER2-overexpressed breast can-
cer patients. There are increasingly demands among the 
patients with HER2 overexpression who could be benefit 
on those standard treatments, but that is limited by the 
risk of drug shortages, which may greatly affect patient 
care and health care cost (Li et  al. 2015), therefore bio-
similars are pursued with great interest. The biosimi-
lar product of trastuzumab (Cipterbin®) was developed 
by Shanghai CP Guojian Pharmaceutical Co. in China. 
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Recombinant humanized anti-HER2 monoclonal anti-
body (rhuHER2mAb, Cipterbin®), a IgG1-κ antibody, 
with the complementarity determining region derived 
from a mouse anti-HER2 antibody and the rest parts 
from the human IgG1-κ antibody, which has the same 
binding sites and mechanism of action as Trastuzumab.
For this study, we have conducted a single institution, 
open labeled, phase I study. The primary objectives were 
designed to evaluate safety and toxicity of Cipterbin®. 
The secondary objective included pharmacokinetic eval-




The patients were enrolled in Beijing Cancer Hospital 
from December 2004 to May 2005 under the circumstance 
of approved phase I clinical trial by China Food and Drug 
Administration of China. Enrolled patients were all women 
aged from 18–70 years with histological confirmed meta-
static lesions Patients were required to have the evidence 
of overexpression HER2 (2+ or 3+) as determined by 
immonohistochemical staining(at least 10 % of carcinoma 
cells exhibited characteristic membrane staining). The 
main points of inclusive criteria was lacking of previously 
antitumor therapy within 4  weeks (6  weeks for mitomy-
cin or nitrosureas). Eastern Cooperative Oncology Group 
(ECOG) performance status of less than 2; estimated life 
expectancy at least more than 3  months; adequate bone 
marrow, liver, and renal function were required. Patients 
with history of severe cardiac disease, central nervous sys-
tem metastasis, active infections, pregnancy or lactation, 
previous therapy with similar monoclonal antibody, or 
concomitant use of any investigation agent were excluded. 
All patients signed the informed consent approved by the 
Ethics Committee of Beijing Cancer Hospital.
Study design
This was a randomized, open label, dose-escalation study. 
As the study protocol designed 10  years ago, we had 
referred to few published literatures of transtuzumab 
(Herceptin®) and conducted this single arm phase I 
trial at that time. The three escalated dosage levels were 
100, 250 and 500 mg, and each level assigned 9 patients, 
totally 27 patients enrolled in this study. Each patient 
was received single dose of Cipterbin® without any other 
anticancer therapy, and followed up until 70 days. During 
the study, peripheral blood tests and urine analyses were 
performed as the protocol required.
Safety assessments
All patients underwent echocardiography during 
screening. Vital signs (blood pressure, pulse rate, 
temperature, and weight), physical examination (with 
particular attention to the cardiovascular system) and 
12-lead electrocardiograms (ECG) were conducted 
throughout the study regularly (0.5, 2, 12, 24  h and 
every week during follow-up time of 70  days). Labo-
ratory testing (hematology and biochemistry) were 
conducted at baseline, 24  h after first administration 
and every week during follow-up time. Ultrasound 
cardiograph used for left ventricular ejection fraction 
(LVEF) assessment was conducted at baseline and the 
end of study. The drug-related adverse events (AEs) 
were scored by National Cancer Institute Common 
Toxicity Criteria (CTCAE, Version 3.0). Drug-related 
AE was defined as the AE has possible or suspicious 
association with study treatment determined by the 
investigators.
Pharmacokinetics
Blood samples for serum concentration of Cipterbin® 
(anti-Her2rhMAb) were collected before dosing, at 0.5, 2, 
4, 8, 12, 24, 36 h and at 2, 3, 5, 7, 9, 11, 14, 21, 28, 35, 42, 
49, 56, 63 days after first dosing. Serum levels of Cipter-
bin® were determined using a validated enzyme-linked 
immunosorbent assay (ELISA).
The Pharmacokinetics data were analyzed by Bei-
jing Shijitan Hospital. All pharmacokinetic parameters 
were calculated by non-compartmental analysis based 
on serum concentration of Cipterbin® using Excel 2000 
(Mircosoft, Redmond, Washington). SAS version 8.2 
(SAS Institute Inc, Cary, North Carolina, USA) was used 
for statistical analyses, and all analyses were using actual 
time of sampling rather than scheduled times. Pharma-
cokinetic parameters were determined as follow: highest 
drug concentration observed in serum after administra-
tion (Cmax), area under the serum concentration versus 
time curve from time zero to last sampling (AUClast), 
area under the serum concentration versus time curve 
from time zero extrapolated to infinity (AUC0–∞), ter-
minal half-life (t1/2), volume of distribution (Vd) and 
clearance (CL). AUC was calculated using the linear trap-
ezoidal rule. Terminal half-life was also evaluated follow-




A total of 27 patients were enrolled in this study, and 
their characteristics were listed in Table 1. Patients aged 
from 28 to 67 years, and the median age was 51 years. 11 
patients (40.7  %) had three or more sites of metastatic 
disease. Most patients had been pretreated before study 
entry, with a majority of patients (19/27) had received 
chemotherapies for metastatic diseases.
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Safety evaluation
All 27 patients were eligible for assessment including tol-
erability and safety, and 25 of 27 (92.6 %) were encoun-
tered at least one frequency of drug-related AE in the 
study, as summarized in Table 2.
The most frequently drug-related AEs were fever 
(59.3 %), ALT/AST transient increased (22.2 %), chills 
(18.5  %), arrhythmia (18.5  %), without occurrence of 
mortality. In general, Cipterbin® was well-tolerated, 
the majority of the events were mild (grade 1/2) and 
transient, with the exception of one patient experi-
enced serious adverse event of brachycardia in 250 mg 
group.
In this study, one patient suffered Grade 4 revers-
ible sinus bradycardia. This patient was 39  years 
old and without history of any cardiac disease, after 
administrating of single dose of 250 mg (i.e. 6.25 mg/
kg) Cipterbin®, she underwent serious sinus brady-
cardia (lowest heart rate 24/min) with syncope in the 
13th day after drug administration. After treatment 
of promethazine and dexamethasone, the patient 
had been fully recovered. Other drug-related cardiac 
toxicities were mild and not intervention indicated, 
including three palpitation, three sinus bradycar-
dia and one junctional premature beat. No signifi-
cant decline in LVEF and no congestive heart failure 
Table 1 Patient characteristics
Characteristic Patients
Total (n = 27) 100 mg (n = 9) 250 mg (n = 9) 500 mg (n = 9)
No. % No. % No. % No. %
Age, years
 Mean 51 51 53 49
 Range 28–67 40–67 36–64 28–63
ECOG performance status
 0 18 66.7 8 88.9 5 55.6 5 55.6
 1 9 33.3 1 11.1 4 44.4 4 44.4
Level of HER2/neu overexpression
 2+ 8 29.6 3 33.3 2 22.2 3 33.3
 3+ 19 70.4 6 66.7 7 77.8 6 66.7
Receptor status
 Estrogen receptor-positive (n = 26) 14 53.8 4 44.4 3 37.5 7 77.7
 Progesterone receptor-positive (n = 26) 9 34.6 3 33.3 2 25.0 4 44.4
Menopausal status
 Premenopausal 7 25.9 1 11.1 3 33.3 3 33.3
 Postmenopausal 18 66.7 6 66.7 6 66.7 6 66.7
 Perimenopausal 2 7.4 2 22.2 0 0
No. of metastatic sites
 1 10 37.0 2 22.2 4 44.4 4 44.4
 2 6 22.2 2 22.2 2 22.2 2 22.2
 ≥3 11 40.7 5 55.6 3 33.3 3 33.3
Dominant site of metastasis
 Bone 15 55.6 5 55.6 4 44.4 6 66.7
 Lymph node 12 44.4 5 55.6 4 44.4 3 33.3
 Viscera 10 37.0 5 55.6 2 22.2 3 33.3
No. of prior chemotherapy regimens for metastatic disease
 None 8 29.6 0 3 33.3 5 55.6
 1 14 51.9 5 55.6 6 66.7 3 33.3
 2 5 18.5 4 44.4 0 1 11.1
 Prior hormonal therapy 13 48.1 8 88.9 2 22.2 3 33.3
 Prior radiotherapy 15 55.6 4 44.4 6 66.7 5 55.6
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occurred and there was no treatment-related death in 
this study.
Pharmacokinetic analysis
The serum concentration—time profiles of Cipterbin® 
after first administration with each dose were shown in 
Fig. 1, and the pharmacokinetic properties of each dose 
were summarized in Table  3. As the mean serum con-
centration—time profiles, Cmax values occurred within 
2 h after start of infusion, and subsequent rapid decline 
of serum concentration of Cipterbin® was followed by a 
slower elimination phase. Cmax, AUC0–672 and AUC0–∞ 
were approximately dose-proportional manner. Termi-
nal half-lives were increased in linear but less than dose 
proportional manner. Vd and CL were independent of 
dose. The peak value of Vd and CL happened at the dose 
of 250 mg.
Discussion
More and more accumulative data from the different 
clinical trials demonstrate the efficacy of trastuzumab 
among the patients with HER2 overexpression. Since the 
patent exclusivity rights for trastuzumab has expired in 
Europe and will lose in the United Stated in 2019, a num-
ber of biosimilars trastuzumab are undergoing the pre-
clinical and clinical trials in different countries (Yin et al. 
Table 2 Number of patients with drug-related adverse events
Total (n = 27) 100 mg (n = 9) 250 mg (n = 9) 500 mg (n = 9)
Rang 1.35–1.89 mg/kg Rang 3.65–6.25 mg/kg Rang 6.41–11.11 mg/kg
Grade 1/2 No. 
(%)
Grade 3/4 No. 
(%)
Grade 1/2 No. 
(%)
Grade 3/4 No. 
(%)
Grade 1/2 No. 
(%)
Grade 3/4 No. 
(%)
Grade 1/2 No. 
(%)
Grade 3/4 No. 
(%)




6 (22.2) 0 1 (11.1) 0 3 (33.3) 0 2 (22.2) 0
Chills 5 (18.5) 0 2 (22.2) 0 2 (22.2) 0 1 (11.1) 0
Arrhythmia 5 (18.5) 1 (3.7) 2 (22.2) 0 2 (22.2) 1 (11.1) 0 0
Fatigue 4 (14.8) 0 1 (11.1) 0 2 (22.2) 0 1 (11.1) 0
Dyspnea 4 (14.8) 0 1 (11.1) 0 3 (33.3) 0 0 0
Arthralgia 4 (14.8) 0 2 (22.2) 0 2 (22.2) 0 0 0
Nausea/vomit-
ing
3 (11.1) 0 1 (11.1) 0 2 (22.2) 0 0 0
Palpitation 3 (11.1) 0 1 (11.1) 0 2 (22.2) 0 0 0
Headache 2 (7.4) 0 2 (22.2) 0 0 0 0 0
Dry mouth 2 (7.4) 0 1 (11.1) 0 0 0 1 (11.1) 0
Rash 2 (7.4) 0 1 (11.1) 0 1 (11.1) 0 0 0
Fig. 1 Serum concentration—time profiles. The figure showed the 
serum concentration—time of Cipterbin® at each does level, Cmax 
values occurred within 2 h after start of infusion, and subsequent 
rapid decline of serum concentration of Cipterbin® was followed by a 
slower elimination phase
Table 3 Pharmacokinetic parameters of  Cipterbin® 
after single dose administration
Data are shown as mean ± SD






AUC0–672 µg h/mL 4304 ± 1220 7368 ± 2142 22,386 ± 6774
AUC0–∞ µg h/mL 4510 ± 1214 7615 ± 2203 23,349 ± 7615
t1/2 h 81 ± 13 112 ± 20 144 ± 25
CL mL kg/d 8.6 ± 1.7 13.5 ± 4.4 9.0 ± 2.8
Vd mL/kg 38.1 ± 6.2 74.0 ± 18.4 63.3 ± 18.9
Cmax µg/mL 38.1 ± 7.4 72.5 ± 12.8 173.9 ± 23.8
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2014; Lopez-Morales et  al. 2015; Wisman et  al. 2014; 
Akbarzadeh-Sharbaf et  al. 2012), and their pharmacoki-
netic features, efficacy and pharmacovigilance issues are 
arousing greater attention (Thill 2015; Cortes et al. 2014). 
We demonstrated the phase I data which finished over 
the past 10 years since the phase III data have just been 
achieved and the manufacturer approved to release the 
study data.
The comparison of the molecular structure between 
Herceptin® and Cipterbin® showed that the homology 
was similar in the domain of variable region of antigen 
binding, and the affinity and antigen binding profiles 
were similar in vitro. In this study, PK analysis data has 
displayed an approximately dose-proportional manner, 
except Vd and CL, which reached peak values at 250 mg 
administration cohort. Previous studies suggested that 
trastuzumab clearance related with baseline levels of cir-
culating extracellular domain of the HER2 receptor or the 
number of metastatic sites in patients (Bruno et al. 2005).
Published evidence demonstrates that AEs of trastu-
zumab are mild and manageable when given as mono-
therapy or in combination with other treatments. The 
most commonly AEs are infusion-related reactions which 
including fever, chills, headache and other flu-like symp-
toms, often occurred within 24  h after infusion (Boek-
hout et  al. 2011). 59.3  % patients in our study suffered 
from fever, which is higher than the patients treated with 
Herceptin in previous studies (up to 40 %)(Chung 2008; 
Cook-Bruns 2001), but these AEs were generally mild 
and transient, and the flu-like symptoms could be man-
aged well with anti-inflammatory drugs when necessary.
Cardiac dysfunction is an important safety issue in tras-
tuzumab treatment. From long-term cardiac safety data 
from large-scale randomized adjuvant trastuzumab trials, 
the incidence of symptomatic heart failure events was about 
2  % in trasuzumab-treated with patients HER2-positive 
breast cancer. And the elder age (>50) and lower left ven-
tricular ejection fraction (LVEF) (<50 %) at the baseline of 
trastuzumab treatment were closely associated with the 
higher rate of congestive heart failure (Russell et al. 2010). 
Our study design was intended to mitigate the risk of symp-
tomatic heart failure by strictly selecting the patients has 
normal LVEF and carefully monitoring of cardiac function, 
and no significant decline in LVEF was observed in this 
study. Even though, the drug-related cardiotoxicities were 
still warranted. At present, echocardiographic measures and 
ECGs are used as the basic requirements, and some bio-
markers have be comfirmed as the value predictors for pre-
cise evaluation of cardiotoxicities, such as the plasma level 
of N-terminal pro B type natriuretic peptide(NT-proBNP) 
and troponin (Perik et al. 2006; Cardinale et al. 2010).
In our study, 22.2  % patients occurred transient 
increase of serum aminotransferase levels at 24  h after 
infusion, and then these liver enzymes restored to normal 
within 14  days without medication, these cases resem-
bled as rare report of trastuzumab-induced hepatotoxic-
ity (Munoz et  al. 2007; Srinivasan et  al. 2008; Vucicevic 
et al. 2013). It should be noticed that the phase I study of 
a HER2 tyrosine kinase inhibitor CP-724 could elicit 66 % 
at least grade 1 hepatic toxicity (Guo et al. 2008). There 
was increasingly demand that the regular examination 
of liver function should be placed to avoid the asympto-
matic appearance due to drug induced liver injury. More-
over molecular target reagents were capable of inducing 
the potential liver injury while much attention was paid 
in cardiotoxicities.
Conclusions
We have primarily conducted this phase I trial and the 
major conclusion could be drawn that such biosimilar 
product was shown well-tolerated. We have admitted 
to say that although those data of phase I trial were col-
lected in 10 years ago, the results still constitute the basis 
for the design of subsequent phase II and phase III clini-
cal studies. The further efficacy and safety assessments 
should be warranted.
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